206
Views
0
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Assessing the Health Economic Outcomes from Commercially Insured Relapsing Multiple Sclerosis Patients Who Switched from Other Disease-Modifying Therapies to Teriflunomide, in the United States

ORCID Icon, , , &
Pages 361-373 | Received 27 Jan 2023, Accepted 02 May 2023, Published online: 20 May 2023

Reprints and Permissions

Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.

To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.

For more information please visit our Permissions help page.